Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.

Takeuchi Y, Kuroda T, Sugimoto T, Shiraki M, Nakamura T

Calcified tissue international19 Oct 2015Cited by 4 (Europe PMC)

PMID26478225PMCIDPMC4723624DOI10.1007/s00223-015-0073-7PepBankPUB-26478225

Summary

In order to assess the changes in serum calcium and phosphate and the changes in renal tubular phosphate reabsorption (TmP/GFR) and to evaluate the association between these indices and the increase in bone mineral density (BMD) with once-weekly intermittent administration of teriparatide (TPTD), the results from the teriparatide once-weekly efficacy research (TOWER) trial were re-analyzed. The TOWER trial studied postmenopausal women and older men with osteoporosis. Patients were randomly assigned to receive TPTD 56.5 μg or placebo for 72 weeks. Of these patients, the present study investigated those whose calcium and phosphate levels and lumbar BMD (L-BMD) were measured (TPTD group, n = 153 and Placebo group, n = 137). The TPTD group had significantly lower serum phosphate, calcium-phosphate product, and TmP/GFR at weeks 4, 24, 48, and 72 and urinary fractional calcium excretion (FECa) at weeks 12, 48, and 72 (p < 0.05). In the TPTD group, the serum phosphate and TmP/GFR during early treatment (4, and 12 weeks) showed a significant positive correlation with the percent change in L-BMD at weeks 48 and 72. Based on multivariate analysis corrected for age, BMI, and L-BMD at the start of treatment, serum phosphate and TmP/GFR at week 4 showed a significant correlation with the percent change in L-BMD. This study suggests that the L-BMD response to once-weekly long-term TPTD treatment is associated with circulating phosphate or with the status of its renal reabsorption. Preventing decrease in serum phosphate levels may be important in acquiring greater L-BMD with once-weekly TPTD.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, serum phosphate was lower with teriparatide than with placebo at weeks 4, 24, 48, and 72.
In plain wordsIn osteoporosis patients, serum phosphate was lower with teriparatide than with placebo at weeks 4, 24, 48, and 72.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum phosphate
Study
n = 290
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
The TPTD group had significantly lower serum phosphate, calcium-phosphate product, and TmP/GFR at weeks 4, 24, 48, and 72 and urinary fractional calcium excretion (FECa) at weeks 12, 48, and 72 (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The TOWER trial studied postmenopausal women and older men with osteoporosis. Patients were randomly assigned to receive TPTD 56.5 μg or placebo for 72 weeks. Of these patients, the present study investigated those whose calcium and phosphate levels and lumbar BMD (L-BMD) were measured (TPTD group, n = 153 and Placebo group, n = 137).
Show in the study text Report a problemFND-2647822501
02HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, calcium-phosphate product was lower with teriparatide than with placebo at weeks 4, 24, 48, and 72.
In plain wordsIn osteoporosis patients, calcium-phosphate product was lower with teriparatide than with placebo at weeks 4, 24, 48, and 72.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCalcium-phosphate product
Study
n = 290
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
The TPTD group had significantly lower serum phosphate, calcium-phosphate product, and TmP/GFR at weeks 4, 24, 48, and 72 and urinary fractional calcium excretion (FECa) at weeks 12, 48, and 72 (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The TOWER trial studied postmenopausal women and older men with osteoporosis. Patients were randomly assigned to receive TPTD 56.5 μg or placebo for 72 weeks. Of these patients, the present study investigated those whose calcium and phosphate levels and lumbar BMD (L-BMD) were measured (TPTD group, n = 153 and Placebo group, n = 137).
Show in the study text Report a problemFND-2647822502
03HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, TmP/GFR was lower with teriparatide than with placebo at weeks 4, 24, 48, and 72.
In plain wordsIn osteoporosis patients, renal phosphate reabsorption (TmP/GFR) was lower with teriparatide than with placebo at weeks 4, 24, 48, and 72.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRenal tubular phosphate reabsorption
Study
n = 290
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
The TPTD group had significantly lower serum phosphate, calcium-phosphate product, and TmP/GFR at weeks 4, 24, 48, and 72 and urinary fractional calcium excretion (FECa) at weeks 12, 48, and 72 (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The TOWER trial studied postmenopausal women and older men with osteoporosis. Patients were randomly assigned to receive TPTD 56.5 μg or placebo for 72 weeks. Of these patients, the present study investigated those whose calcium and phosphate levels and lumbar BMD (L-BMD) were measured (TPTD group, n = 153 and Placebo group, n = 137).
Show in the study text Report a problemFND-2647822503
04HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, urinary fractional calcium excretion was lower with teriparatide than with placebo at weeks 12, 48, and 72.
In plain wordsIn osteoporosis patients, urinary fractional calcium excretion was lower with teriparatide than with placebo at weeks 12, 48, and 72.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrinary fractional calcium excretion
Study
n = 290
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
The TPTD group had significantly lower serum phosphate, calcium-phosphate product, and TmP/GFR at weeks 4, 24, 48, and 72 and urinary fractional calcium excretion (FECa) at weeks 12, 48, and 72 (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The TOWER trial studied postmenopausal women and older men with osteoporosis. Patients were randomly assigned to receive TPTD 56.5 μg or placebo for 72 weeks. Of these patients, the present study investigated those whose calcium and phosphate levels and lumbar BMD (L-BMD) were measured (TPTD group, n = 153 and Placebo group, n = 137).
Show in the study text Report a problemFND-2647822504

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In teriparatide-treated osteoporosis patients, early serum phosphate correlated positively with lumbar BMD change at weeks 48 and 72.
In plain wordsIn teriparatide-treated osteoporosis patients, higher early serum phosphate was linked to greater later lumbar bone density increases.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEarly serum phosphate association with later BMD change
Study
n = 153
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
In the TPTD group, the serum phosphate and TmP/GFR during early treatment (4, and 12 weeks) showed a significant positive correlation with the percent change in L-BMD at weeks 48 and 72.
1 context sentence(design, population, supporting numbers)
Summary · context
The TOWER trial studied postmenopausal women and older men with osteoporosis. Patients were randomly assigned to receive TPTD 56.5 μg or placebo for 72 weeks. Of these patients, the present study investigated those whose calcium and phosphate levels and lumbar BMD (L-BMD) were measured (TPTD group, n = 153 and Placebo group, n = 137).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-2647822505
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In teriparatide-treated osteoporosis patients, early TmP/GFR correlated positively with lumbar BMD change at weeks 48 and 72.
In plain wordsIn teriparatide-treated osteoporosis patients, higher early renal phosphate reabsorption was linked to greater later lumbar bone density increases.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEarly TmP/GFR association with later BMD change
Study
n = 153
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
In the TPTD group, the serum phosphate and TmP/GFR during early treatment (4, and 12 weeks) showed a significant positive correlation with the percent change in L-BMD at weeks 48 and 72.
1 context sentence(design, population, supporting numbers)
Summary · context
The TOWER trial studied postmenopausal women and older men with osteoporosis. Patients were randomly assigned to receive TPTD 56.5 μg or placebo for 72 weeks. Of these patients, the present study investigated those whose calcium and phosphate levels and lumbar BMD (L-BMD) were measured (TPTD group, n = 153 and Placebo group, n = 137).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-2647822506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.